首页> 美国卫生研究院文献>PPAR Research >Potential Therapeutic Use of PPARγ-Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy
【2h】

Potential Therapeutic Use of PPARγ-Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy

机译:PPARγ编程的人类单核细胞衍生树突状细胞在癌症疫苗治疗中的潜在治疗用途

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone receptors, and amongst them the lipid-activated nuclear receptor and peroxisome proliferator-activated receptor gamma (PPARγ), have important roles in effecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via this it influences the immunophenotype of DCs by altering lipid antigen uptake, presentation, and also other immune functions. In this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPARγ-regulated processes might be involved and could be exploited in the design of vaccination strategies.
机译:树突状细胞(DC)可以调节免疫系统的所有元素,因此是接种疫苗的理想靶标。在过去的二十年中,由于进行了广泛的研究,DC也成为抗肿瘤疫苗接种的主要目标。抗肿瘤疫苗接种的关键问题是所用树突状细胞的表型。最近已经显示出几种核激素受体,其中包括脂质激活的核受体和过氧化物酶体增殖物激活的受体γ(PPARγ),在影响人树突细胞的免疫表型中起重要作用。它主要调节脂质代谢,并通过改变脂质抗原的摄取,呈递以及其他免疫功能来影响DC的免疫表型。在这篇综述中,我们总结了抗肿瘤疫苗接种策略的原理,并提出了关于PPARγ调控过程如何参与疫苗接种策略设计的假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号